Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacinase
- Development stage
- Unknown
- Lead developer
- Guilin Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacinase (also known as Lactasin) is an oral probiotic preparation containing live Enterococcus faecalis (formerly Streptococcus faecalis) or Enterococcus faecium. Developed and manufactured by Guilin Pharmaceutical, it is widely used as an over-the-counter (OTC) digestive aid in China. Upon oral administration, the live bacteria colonize the intestinal tract and ferment sugars to produce lactic acid. This increases intestinal acidity, which in turn inhibits the proliferation of pathogenic and spoilage bacteria, prevents abnormal fermentation, and reduces intestinal gas. Lactobacinase is primarily indicated for the treatment of dyspepsia (indigestion), abdominal distension (bloating), and diarrhea or green stools caused by dietary dysfunction, particularly in pediatric patients.
- Other names
- BioferminBiofermineLactasinLactasinum乳酶生乳酶生片
Beyond the preview
Go deeper on lactobacinase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacinase.